Metabolic and Cognitive Effects of Ranolazine in Type 2 Diabetes Mellitus: Data from an in vivo Model

Type 2 diabetes mellitus (T2DM) is a risk factor for cognitive impairment. Ranolazine, an anti-ischemic drug used in the treatment of angina pectoris, has been shown to possess hypoglycemic properties in pre-clinical and clinical studies. The aim of this study was to evaluate the effects of ranolazi...

Descripción completa

Detalles Bibliográficos
Autores principales: Cassano, Velia, Leo, Antonio, Tallarico, Martina, Nesci, Valentina, Cimellaro, Antonio, Fiorentino, Teresa Vanessa, Citraro, Rita, Hribal, Marta Letizia, De Sarro, Giovambattista, Perticone, Francesco, Sesti, Giorgio, Russo, Emilio, Sciacqua, Angela
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7071286/
https://www.ncbi.nlm.nih.gov/pubmed/32023991
http://dx.doi.org/10.3390/nu12020382

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7071286/
https://www.ncbi.nlm.nih.gov/pubmed/32023991
http://dx.doi.org/10.3390/nu12020382

Ejemplares similares